<?xml version="1.0" encoding="UTF-8"?>
<p id="para0020">Despite the paucity of firm data on direct myocardial involvement in COVID-19 patients, there are ample data on secondary involvement of the cardiovascular system, manifesting as elevated blood levels of cardiac enzymes; such as cardiac troponin I and B-type natriuretic peptide, regional and global wall motion abnormalities, cardiac arrhythmias, intravascular thrombosis, and heart failure (reviewed in [
 <xref rid="bib0033" ref-type="bibr">33</xref>,
 <xref rid="bib0034" ref-type="bibr">34</xref>,
 <xref rid="bib0035" ref-type="bibr">35</xref>]). More importantly, concomitant cardiovascular disease and secondary cardiac involvement are major determinants of clinical outcomes, including mortality in patients with COVID-19 [
 <xref rid="bib0036" ref-type="bibr">36</xref>,
 <xref rid="bib0037" ref-type="bibr">37</xref>].
</p>
